Global Hereditary Angioedema Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Hereditary Angioedema Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Hereditary Angioedema Drug market size was valued at USD 764.5 million in 2023 and is forecast to a readjusted size of USD 1188.6 million by 2030 with a CAGR of 6.5% during review period.

In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Hereditary Angioedema Drug industry chain, the market status of Retail Pharmacies (C1 Esterase Inhibitor, Kallikrein Inhibitor), Hospital Pharmacies (C1 Esterase Inhibitor, Kallikrein Inhibitor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Hereditary Angioedema Drug.

Regionally, the report analyzes the Hereditary Angioedema Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Hereditary Angioedema Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Hereditary Angioedema Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Hereditary Angioedema Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., C1 Esterase Inhibitor, Kallikrein Inhibitor).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Hereditary Angioedema Drug market.

Regional Analysis: The report involves examining the Hereditary Angioedema Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Hereditary Angioedema Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Hereditary Angioedema Drug:

Company Analysis: Report covers individual Hereditary Angioedema Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Hereditary Angioedema Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Retail Pharmacies, Hospital Pharmacies).

Technology Analysis: Report covers specific technologies relevant to Hereditary Angioedema Drug. It assesses the current state, advancements, and potential future developments in Hereditary Angioedema Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Hereditary Angioedema Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Hereditary Angioedema Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Market segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Major players covered
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Hereditary Angioedema Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Hereditary Angioedema Drug, with price, sales, revenue and global market share of Hereditary Angioedema Drug from 2019 to 2024.

Chapter 3, the Hereditary Angioedema Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Hereditary Angioedema Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Hereditary Angioedema Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Hereditary Angioedema Drug.

Chapter 14 and 15, to describe Hereditary Angioedema Drug sales channel, distributors, customers, research findings and conclusion.